<DOC>
	<DOCNO>NCT02218554</DOCNO>
	<brief_summary>To evaluate performance Micromedic BRONJ Risk Assessment vitro assay ( `` BRONJ Assay '' ) identify Multiple Myeloma ( MM ) and/or cancer subject risk develop Bisphosphonate-related Osteonecrosis Jaw ( BRONJ ) follow intravenous ( IV ) administration Bisphosphonates ( BP ) .</brief_summary>
	<brief_title>Performance Evaluation Micromedic BRONJ Risk Assessment Vitro Diagnostic Assay</brief_title>
	<detailed_description>The Micromedic BRONJ Assay intend qualitative analysis genetic change may indicative increase risk develop BRONJ osteonecrosis jaw ( ONJ ) follow IV administration drug Bisphosphonate family .</detailed_description>
	<mesh_term>Osteonecrosis</mesh_term>
	<mesh_term>Bisphosphonate-Associated Osteonecrosis Jaw</mesh_term>
	<criteria>Inclusion Criteria Study Group ( follow ) : 1 . Subject ≥18 year old 2 . Subject Multiple Myeloma and/or cancer patient IV treat BP zoledronic acid and/or pamidronate disodium ; Or ; Subject Multiple Myeloma and/or cancer patient IV treat BP zoledronic acid and/or pamidronate disodium also treat oral BP sodium alendronate , opinion PI , IV treatment significant enough consider cause BRONJ 3 . Subject diagnose BRONJ stage 1 2 3 accord AAOMS ( American Association Oral Maxillofacial Surgeons ) 4 . Subject sign informed consent consent waive Inclusion Criteria Control Group ( follow ) : 1 . Subject ≥18 year old 2 . Subject Multiple Myeloma and/or cancer patient , IV treat BP zoledronic acid and/or pamidronate disodium least two ( 2 ) year ( continuously cumulatively ) 3 . Subject develop sign symptom BRONJ 4 . Subject sign informed consent consent waive 1 . Subject treated irradiation jaw head neck level exceed 35 Gy 2 . Pregnant lactate woman 3 . Subject treat either bevacizumab sunitimib 4 . Subject treat Allogeneic hematopoietic stem cell transplantation ( HSCT )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>BRONJ</keyword>
</DOC>